By comparing the p-value and hazard ratio, we analyzed the impact of each key gene on the survival of PRAD patients, and we selected MIOX as a hub gene regulating PRAD metabolic disorders (p = 0.019, HR = 1.193). This evidence concerns the gene MIOX and prostate adenocarcinoma.